Anifrolumab Shows Promise in Refractory Discoid Lupus

The study evaluated the records of eight women with DLE recalcitrant to standard therapies who were treated with anifrolumab for at least 8 weeks.
MDedge News

source https://www.medscape.com/viewarticle/990155?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost